Program
nogapendekin alfa inbakicept
Also written as “ALT-803”, “N-803” and “Nogapendekin alfa inbakicept (NAI)”.
Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Non-Muscle Invasive Bladder Neoplasms · Triple Negative Breast Neoplasms · Carcinoma, Transitional Cell, led by ImmunityBio.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ImmunityBio | 4511 open or running | phase 3since Jan 13, 2017 | Sep 11, 2013 | Nov 2026phase 2 · NCT06829823 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 32 studies since Sep 11, 2013.
- Jun 26, 2023Phase 1 study in Healthy SubjectsNCT06040918 · 10 enrolled · United States
- Dec 17, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06745908 · 507 planned · United States, Canada, United Kingdom
- Feb 5, 2025Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT06829823 · 20 planned
- Jul 30, 20252 phase 2 studies in Post-Acute COVID-19 SyndromeNCT07123727, NCT07108036
- Sep 18, 2025Phase 3 study in Community-Acquired PneumoniaNCT07492875
- Oct 14, 2025Phase 1 study in Carcinoma, Transitional CellNCT07217496 · 18 planned · United States
- Nov 20, 2025Phase 1 study in Pancreatic NeoplasmsNCT07488884
- Mar 26, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07524257
- Apr 20, 2026Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNCT07551544
- May 5, 2026Phase 2 study in SepsisNCT07578558
- Jun 1, 2026Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07628062 · 70 planned
- Aug 21, 2026Phase 2 study in SepsisNCT07783789 · 50 planned
- Sep 25, 2026Primary completion moved from 2027-10-12 to 2028-05-12Date moved laterphase 2 · +7 months · NCT07783789
- Nov 17, 2026Phase 2 study withdrawnStudy stoppedNCT07578558 · “Sponsor decision”
Ahead
- Nov 2026Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT06829823
- Mar 2027Primary completion: phase 2 study in Post-Acute COVID-19 SyndromeNCT07123727
- Jan 2028Primary completion: phase 1 study in Carcinoma, Transitional CellNCT07217496
- May 12, 2028Primary completion: phase 2 study in SepsisNCT07783789
TargetBeta
“A fusion protein soluble complex and interleukin-15 (IL-15) receptor agonist composed of nogapendekin alfa, a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D) and inbakicept, a fusion protein containing a dimeric IL-15 receptor alpha (IL-15Ra) sushi domain ”NCIt, by rule
“Interleukin-15 receptor agonist”ChEMBL 37, by rule
Studies
All 45 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07783789Sepsis | 2 | Not yet recruiting | May 12, 2028 | 50 |
| NCT07628062Squamous Cell Carcinoma of Head and Neck | 2 | Not yet recruiting | Dec 31, 2030 | 70 |
| NCT07578558Sepsis | 2 | Withdrawn | Aug 3, 2027 | 0 |
| NCT07551544Non-Muscle Invasive Bladder Neoplasms | 3 | Withdrawn | May 2032 | 0 |
| NCT07524257Carcinoma, Non-Small-Cell Lung | 3 | Withdrawn | May 15, 2029 | 0 |
| NCT07488884Pancreatic Neoplasms | 1 | Withdrawn | Jun 1, 2027 | 0 |
| NCT07217496Carcinoma, Transitional Cell · United States | 1 | Not yet recruiting | Jan 2028 | 18 |
| NCT07492875Community-Acquired Pneumonia | 3 | Withdrawn | Apr 15, 2029 | 0 |
| NCT07123727Post-Acute COVID-19 Syndrome · United States | 2 | Recruiting | Mar 2027 | 40 |
| NCT07108036Post-Acute COVID-19 Syndrome · United States | 2 | Recruiting | Oct 2026 | 20 |
| NCT06829823Non-Muscle Invasive Bladder Neoplasms | 2 | Not yet recruiting | Nov 2026 | 20 |
| NCT06745908Carcinoma, Non-Small-Cell Lung · United States, Canada, United Kingdom | 3 | Recruiting | Sep 2028 | 507 |
| NCT06040918Healthy Subjects · United States | 1 | Completed | Sep 3, 2024 | 10 |
| NCT04390399Pancreatic Neoplasms · United States | 2 | Active, not recruiting | Oct 13, 2025 | 328 |
| NCT04385849COVID-19 · United States | 1 | Terminated | Jul 25, 2020 | 1 |
| NCT03853317Carcinoma, Merkel Cell · United States | 2 | Terminated | Sep 29, 2021 | 9 |
| NCT03647423Chordoma · United States | 2 | Withdrawn | Aug 31, 2020 | 0 |
| NCT03586869Pancreatic Neoplasms · United States | 2 | Terminated | Apr 17, 2019 | 3 |
| NCT03574649Carcinoma, Non-Small-Cell Lung · United States | 2 | Withdrawn | Aug 2018 | 0 |
| NCT03563144Pancreatic Neoplasms · United States | 2 | Withdrawn | Dec 30, 2019 | 0 |
| NCT03554109Triple Negative Breast Neoplasms · United States | 2 | Withdrawn | Jun 2020 | 0 |
| NCT03563170Hepatocellular Carcinoma Non-resectable · United States | 2 | Withdrawn | Aug 23, 2019 | 0 |
| NCT03387111Carcinoma, Squamous Cell · United States | 2 | Terminated | Apr 17, 2019 | 4 |
| NCT03387098Pancreatic Neoplasms · United States | 2 | Terminated | Sep 12, 2018 | 4 |
| NCT03387085Triple Negative Breast Neoplasms · United States | 2 | Terminated | Sep 11, 2020 | 9 |
| NCT03381586Healthy · United States | 1 | Completed | Mar 13, 2018 | 20 |
| NCT03329248Pancreatic Neoplasms · United States | 2 | Terminated | Aug 13, 2018 | 6 |
| NCT03228667Carcinoma, Non-Small-Cell Lung · United States | 2 | Active, not recruiting | Aug 31, 2029 | 40 |
| NCT03197584Ovarian Neoplasms | 2 | Withdrawn | Feb 2019 | 0 |
| NCT03197571Carcinoma, Transitional Cell | 2 | Withdrawn | Jan 2019 | 0 |
| NCT03175666Triple Negative Breast Neoplasms | 2 | Withdrawn | Jan 2019 | 0 |
| NCT03169790Lymphoma, Non-Hodgkin | 2 | Withdrawn | Jan 2019 | 0 |
| NCT03169777Colorectal Neoplasms | 2 | Withdrawn | Jan 2019 | 0 |
| NCT03169764Squamous Cell Carcinoma of Head and Neck | 2 | Withdrawn | Jan 2019 | 0 |
| NCT03169738Carcinoma, Non-Small-Cell Lung | 2 | Withdrawn | Jan 2019 | 0 |
| NCT03167177Melanoma | 2 | Withdrawn | Jan 2019 | 0 |
| NCT03167164Carcinoma, Merkel Cell | 2 | Withdrawn | Jan 2019 | 0 |
| NCT03127098Thyroid Neoplasms · United States | 2 | Terminated | Dec 7, 2017 | 3 |
| NCT03136406Pancreatic Neoplasms · United States | 2 | Terminated | Nov 22, 2017 | 3 |
| NCT03022825Urinary Bladder Neoplasms · United States | 3 | Active, not recruiting | Oct 1, 2024 | 190 |
| NCT02559674Neoplasms · United States | 1 | Completed | Feb 21, 2018 | 8 |
| NCT02384954Recurrence · United States | 2 | Terminated | Dec 13, 2020 | 43 |
| NCT02138734Non-Muscle Invasive Bladder Neoplasms · United States, India, South Africa | 2 | Active, not recruiting | Sep 30, 2026 | 369 |
| NCT02099539Recurrence · United States | 1 | Terminated | Jun 19, 2018 | 19 |
| NCT01946789Neoplasms · United States | 1 | Completed | Aug 2017 | 26 |
How it is read
Names in the registry
- “ALT-803”, 21 entries
- “N-803”, 11 entries
- “Nogapendekin alfa inbakicept (NAI)”, 3 entries
- “Nogapendekin Alfa Inbakicept (NAI)”, 2 entries
- “Anktiva”, 1 entry
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 7 studies
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Non-Muscle Invasive Bladder Neoplasms, 4 studies
- Triple Negative Breast Neoplasms, 3 studies
- Carcinoma, Transitional Cell, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.